Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Concert Pharma (CNCE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGNResearch Report), Concert Pharma (CNCEResearch Report) and scPharmaceuticals (SCPHResearch Report) with bullish sentiments.

Regeneron (REGN)

H.C. Wainwright analyst Michael King reiterated a Buy rating on Regeneron today and set a price target of $703.00. The company’s shares closed last Thursday at $574.62.

According to TipRanks.com, King is a 5-star analyst with an average return of 29.7% and a 57.5% success rate. King covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Inc., Intellia Therapeutics, and Agios Pharma.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $637.40.

See today’s analyst top recommended stocks >>

Concert Pharma (CNCE)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Concert Pharma, with a price target of $17.00. The company’s shares closed last Thursday at $4.06, close to its 52-week low of $3.68.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 20.5% and a 54.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Global Blood Therapeutics, and Deciphera Pharmaceuticals.

Currently, the analyst consensus on Concert Pharma is a Strong Buy with an average price target of $12.00, a 183.7% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $13.00 price target.

scPharmaceuticals (SCPH)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on scPharmaceuticals, with a price target of $15.00. The company’s shares closed last Thursday at $7.15.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 19.4% and a 56.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for scPharmaceuticals with a $12.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.